Drug‐Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease

Coronary artery disease is the largest killer of men and women in the United States and costs the health care system billions of dollars annually. Several advances in both mechanical and pharmacologic treatment of coronary artery disease have occurred in recent decades. Mechanically, percutaneous coronary intervention is commonly used to treat coronary atherosclerosis. This approach has dramatically reduced both morbidity and mortality for patients with different levels of severity of coronary artery disease. However, percutaneous coronary intervention is limited by restenosis, which is an increase in growth of the intimal layer of the vessel wall. Despite the introduction of intracoronary stents and the addition of systemic pharmacotherapy, restenosis still affects a significant number of patients. The new technology of drug‐eluting stents combines mechanical and pharmacologic approaches to prevent restenosis. Various types of these stents exist in different stages of development; several have been shown to prevent or reduce intimal growth after stent deployment. An understanding of how this combined mechanical and pharmacologic approach reduces restenosis requires consideration of complex issues in pathophysiology and pharmacology.

[1]  T. Meerloo,et al.  SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. , 1997, Transplantation.

[2]  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000 .

[3]  M. Eisenberg,et al.  Coated Stents for the Prevention of Restenosis: Part II , 2002, Circulation.

[4]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[5]  P. Serruys,et al.  Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial , 2002, Circulation.

[6]  R. Pakala,et al.  Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. , 1997, Circulation.

[7]  L. Wallentin,et al.  A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. , 2002, Journal of the American College of Cardiology.

[8]  A. Kastrati,et al.  Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.

[9]  W. Siegenthaler,et al.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.

[10]  R. Alexander,et al.  Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[11]  M. Leon,et al.  The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[12]  M. Hooks Tacrolimus, a New Immunosuppressant—A Review of the Literature , 1994, The Annals of pharmacotherapy.

[13]  Larry S. Dean,et al.  Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.

[14]  H Sack,et al.  [Catheter-based radiotherapy to inhibit restenosis after coronary stenting]. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[15]  A. Zalewski,et al.  Transforming Growth Factor-β1 Expression and Myofibroblast Formation During Arterial Repair , 1996 .

[16]  P. Serruys,et al.  Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.

[17]  U. Ikeda,et al.  Acute platelet inhibition with abciximab does not reduce in-stent restenosis. , 2000, Circulation.

[18]  A. Marcus,et al.  Thrombosis and Inflammation as Multicellular Processes: Significance of Cell-Cell Interactions , 1995, Thrombosis and Haemostasis.

[19]  J. Badimón,et al.  Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.

[20]  B R Goldspiel,et al.  Paclitaxel (Taxol) , 1994, Pharmacotherapy.

[21]  S. Schwartz,et al.  Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery , 1985, Circulation research.

[22]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[23]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[24]  P. Serruys,et al.  Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction: A Clinical and Angiographic Study , 2003, Circulation.

[25]  Marcus Aj Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. , 1994 .

[26]  鈴木 健 Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model , 2003 .

[27]  M. Hadamitzky,et al.  Influence of lesion length on restenosis after coronary stent placement. , 1999, The American journal of cardiology.

[28]  P. Serruys,et al.  Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up , 2002, Circulation.

[29]  S. Silber,et al.  Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.

[30]  P. Libby,et al.  Inflammation and thrombosis: the clot thickens. , 2001, Circulation.

[31]  AlbertSchömig,et al.  Vessel Size and Long-Term Outcome After Coronary Stent Placement , 1998 .

[32]  S. Marx,et al.  Bench to bedside: the development of rapamycin and its application to stent restenosis. , 2001, Circulation.

[33]  M. Hadamitzky,et al.  Vessel size and long-term outcome after coronary stent placement. , 1998, Circulation.

[34]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[35]  J. Spinelli,et al.  Improved clinical outcome after widespread use of coronary-artery stenting in Canada. , 1999, The New England journal of medicine.

[36]  N. Weissman,et al.  Paclitaxel Coating Reduces In-Stent Intimal Hyperplasia in Human Coronary Arteries: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT) , 2003, Circulation.

[37]  Rossella Fattori,et al.  Drug-eluting stents in vascular intervention , 2003, The Lancet.

[38]  C. Vassanelli,et al.  [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[39]  P. Fitzgerald,et al.  Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. , 2000, Circulation.

[40]  P. Teirstein,et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.

[41]  Patrick W Serruys,et al.  New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.

[42]  C. Di Mario,et al.  First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.

[43]  M. Eisenberg,et al.  Coated stents for the prevention of restenosis: Part I. , 2002, Circulation.

[44]  P. Fitzgerald,et al.  Novel Drug-Delivery Stent: Intravascular Ultrasound Observations From the First Human Experience With the QP2-Eluting Polymer Stent System , 2001, Circulation.

[45]  I. Palacios,et al.  Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. , 1995, The American journal of cardiology.

[46]  The Esprit investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial , 2000, The Lancet.

[47]  A. N. Mooss,et al.  Restenosis, the Achilles' Heel of Coronary Angioplasty , 1998, Pharmacotherapy.

[48]  J. Isner,et al.  Expression of gax, a Growth Arrest Homeobox Gene, Is Rapidly Down-regulated in the Rat Carotid Artery during the Proliferative Response to Balloon Injury (*) , 1995, The Journal of Biological Chemistry.

[49]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[50]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[51]  Elazer R. Edelman,et al.  Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group , 2002, Circulation.

[52]  A. Becker,et al.  Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. , 1998, Circulation.

[53]  L Chiariello,et al.  A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. , 1997, The New England journal of medicine.

[54]  A. Heldman,et al.  Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial , 2004, Circulation.

[55]  P. Teirstein,et al.  Restenosis After Placement of Palmaz‐Schatz Stents in Native Coronary Arteries: Initial Results of a Multicenter Experience , 1992, Circulation.

[56]  Patrick W Serruys,et al.  Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. , 2003, Journal of the American College of Cardiology.

[57]  W Siegenthaler,et al.  Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. , 1987, The New England journal of medicine.

[58]  A. Baumbach,et al.  Stent‐based antirestenotic coatings (sirolimus/paclitaxel) , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[59]  F. Crea,et al.  Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. , 1998, The American journal of cardiology.

[60]  P. Teirstein,et al.  Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. , 1999, Circulation.

[61]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[62]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[63]  P. Serruys,et al.  Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. , 2003, Journal of the American College of Cardiology.

[64]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[65]  F. Zijlstra,et al.  Sirolimus-eluting coronary stents. , 2004, The New England journal of medicine.

[66]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[67]  Patrick W Serruys,et al.  Fate of side branches after coronary arterial sirolimus-eluting stent implantation. , 2002, The American journal of cardiology.

[68]  S. Marx,et al.  Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. , 1995, Circulation research.

[69]  Jeffrey J. Popma,et al.  Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001, Circulation.

[70]  Julio C. Palmaz,et al.  Clinical Experience With the Palmaz‐Schatz Coronary Stent: Initial Results of a Multicenter Study , 1991, Circulation.

[71]  J. Isner,et al.  The biology of restenosis. , 1997, Progress in cardiovascular diseases.

[72]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[73]  P. Bernatchez,et al.  Estrogen Regulation of Endothelial and Smooth Muscle Cell Migration and Proliferation: Role of p38 and p42/44 Mitogen-Activated Protein Kinase , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[74]  E. Topol Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[75]  J. Krieger,et al.  Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. , 1994, The Journal of clinical investigation.

[76]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[77]  Muzaffer Degertekin,et al.  TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation , 2003, Circulation.

[78]  R. Virmani,et al.  Oral Everolimus Inhibits In-Stent Neointimal Growth , 2002, Circulation.

[79]  J. Brophy Improved clinical outcome after widespread use of coronary-artery stenting in Canada. , 2000, The New England journal of medicine.

[80]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[81]  Levon M Khachigian,et al.  Coronary In-stent Restenosis: Current Status and Future Strategies , 2022 .

[82]  R E Vlietstra,et al.  Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.

[83]  Richard J. Jones Heart Disease: A Textbook of Cardiovascular Medicine , 1980 .

[84]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[85]  E. Vasquez Sirolimus: a new agent for prevention of renal allograft rejection. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[86]  N. Kipshidze,et al.  Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[87]  T. Springer,et al.  Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. , 1996, Blood.

[88]  P. Fitzgerald,et al.  7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE) , 2002, Circulation.

[89]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[90]  M. Leon,et al.  Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future. , 2003, American heart journal.

[91]  P. Serruys,et al.  Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.

[92]  J. Miano,et al.  Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. A putative in vivo mechanism for autocrine growth. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[93]  S. Schwartz,et al.  Production of transforming growth factor beta 1 during repair of arterial injury. , 1991, The Journal of clinical investigation.

[94]  M. Bennett,et al.  Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. , 2001, Pharmacology & therapeutics.

[95]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[96]  P. Serruys,et al.  Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2003, Circulation.

[97]  M. Mann,et al.  Cell cycle progression: new therapeutic target for vascular proliferative disease. , 1998, Circulation.

[98]  F. Fernández‐Avilés,et al.  Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. , 1999, Journal of the American College of Cardiology.

[99]  P. Lund,et al.  Human Protein Disulfide Isomerase Functionally Complements a dsbA Mutation and Enhances the Yield of Pectate Lyase C in Escherichia coli(*) , 1995, The Journal of Biological Chemistry.

[100]  H Yokoi,et al.  Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.

[101]  R. Califf,et al.  Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.

[102]  P. Serruys,et al.  Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size , 2002, Circulation.

[103]  M. Hadamitzky,et al.  Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.

[104]  E. Lakatta,et al.  Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. , 1995, The Journal of clinical investigation.

[105]  J. Gunn,et al.  Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries. , 2002, The Journal of invasive cardiology.

[106]  M. Tendera,et al.  Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial: Polish-American Local Lovenox NIR Assessment Study (The POLONIA Study) , 2001, Circulation.

[107]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[108]  B. Zinman,et al.  Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. , 2004, Diabetes care.

[109]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[110]  M. Nobuyoshi,et al.  Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.

[111]  V. Rajagopal,et al.  Coronary restenosis: a review of mechanisms and management. , 2003, The American journal of medicine.

[112]  Gregg W. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .

[113]  Janita F. J. Vos,et al.  Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. , 2001, European heart journal.

[114]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[115]  M. Baggiolini,et al.  Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[116]  J. Dutcher,et al.  20th‐Century Advances in Drug Therapy in Oncology—Part II , 2000, Journal of clinical pharmacology.

[117]  N. Weissman,et al.  A paclitaxel-eluting stent for the prevention of coronary restenosis. , 2003, The New England journal of medicine.

[118]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[119]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.

[120]  C. Di Mario,et al.  Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. , 1998, Journal of the American College of Cardiology.

[121]  C. Vrints,et al.  Study of antirestenosis with the BiodivYsio dexamethasone‐eluting stent (STRIDE): A first‐in‐human multicenter pilot trial , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[122]  Seung‐Jung Park,et al.  Intravascular ultrasound assessment of patterns of arterial remodeling in the absence of significant reference segment plaque burden in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[123]  H. Gold,et al.  Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. , 2002, Journal of the American College of Cardiology.

[124]  R. Califf,et al.  Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. , 2002, JAMA.

[125]  M. Leon,et al.  Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. , 1997, Cardiology clinics.

[126]  M. Savage,et al.  Restenosis after coronary angioplasty: A multilvariate statistical model to relate lesion and procedure variables to restenosis☆ , 1991 .

[127]  M. Leon,et al.  Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. , 1995, Journal of the American College of Cardiology.

[128]  A. Kastrati,et al.  Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. , 2003, Journal of the American College of Cardiology.

[129]  C. Di Mario,et al.  Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.

[130]  J. Ruiz-Nodar,et al.  Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. DIrect Stenting of COronary Arteries. , 2002, European heart journal.